A hybrid of B and T lymphoblastic cell line could potentially substitute dendritic cells to efficiently expand out Her-2/neu-specific cytotoxic T lymphocytes from advanced breast cancer patients in vitro

To the editor

The current standard way to expand specific cytotoxic T lymphocytes (CTLs) replies obtaining sufficient dendritic cells (DCs) from patients (Additional file 1). This method has several defects such as invasive, time-consuming, expansive, and unstable according to patients’ physical conditions [ 1– 5]. Our group found that the T2 cells, which are a cloned hybrid between the 721.174 (variant of the B lymphoblastic cell line LCL 721) and CEM ^R.3 (variant of T lymphoblastic cell line CEM-C7), potentially conform to the demands. The cells are TAP and MHC class II deficient, but they do express HLA-A2 and massive co-stimulatory molecules (Additional file 2: Figure S1). These characters make T2 cells potentially useful to study CD8 ⁺ T cell recognition of MHC class I antigens, meanwhile, convenient to exclude from MHC class II antigen intervention. Subsequently, HER-2/neu _(369–377) and HER-2/neu _(435–443) which scores more than 20 by SYFPEITHI prediction was selected to load to T2 cells to expand Her-2/neu-specific CD8 ⁺ T cells. HIV gag _(77–85), insulin B chain _(34–42), and HER-2/neu _(39–47) which scores minus 3 were performed as a control (see Additional file 1: Table S1). All peptides except low-affinity peptide HER-2/neu _(39–47) could stabilize HLA-A2 molecules on the cell membrane obviously (Additional file 3: Figure S2A).

After co-culture with CD8 ⁺ T cells from Her-2/neu and HLA-A2 double positive advanced breast cancer patients, HER-2/neu _(369–377)- and HER-2/neu _(435–443)-loaded T2 cells lead to a large secretion of IFN-γ, but not the three controls (Additional file 3: Figure S2B).

For the expansion, starting from 1 × 10 ⁵ total CD8 ⁺ T cells that were less than 0.05% Her-2/neu-specific, nearly 10 ⁷ HER-2/neu _(369–377) or HER-2/neu _(435–443)-specific CD8 ⁺ T cells were expanded out in 8 weeks with the purity of around 85% (Fig.  1a, b). The expanded specific CD8 ⁺ T cells got massive co-stimulatory molecules and activation makers (Fig.  1c). The three controls got negative results. That was expected due to extremely low frequency of naturally occurring HIV gag _(77–85) and insulin B chain _(34–42)-specific naive CD8 ⁺ T cells as indicated in Additional file 3: Figure S2B and low affinity HER-2/neu _(39–47) peptides as showed in Additional file 1: Table S1. We found these expanded HER-2/neu-specific CD8 ⁺ T cells were mainly effector and effector memory cells (Additional file 4: Figure S3).

The expanded Her-2/neu-specific CTL populations mediated dose-dependent lysis to HLA-A2-positive and Her-2/neu-overexpressed breast cancer cell line SK.BR.3, but not to the three control targets (Fig.  2a). The lysis attributed to over 50% perforin producing CTLs and more than 80% granzyme B producing CTLs (Fig.  2b). The cytotoxic activity against SK.BR.3 could significantly be eliminated by W6/32, but not by IgG2 (shown in Fig.  2c).

A major finding of this study was that the Her-2/neu-loaded T2 cells could expand out nearly 10 ⁷ Her-2/neu-specific CTLs in 8 weeks. The expanding efficiency is equivalent to DCs previously reported by Marzocchetti et al. [ 6– 8]. And because the expansion was started from CD8 ⁺ T cells which were only from 5 ml blood, with an initial frequency of Her-2/neu-specific CD8 ⁺ T cells at 0.05%, it would be possible to amplify the expanding quantity if we isolate the Her-2/neu-specific CD8 ⁺ T cells firstly from more blood, 50 ml or more for example.

We found the expanded HER-2/neu-specific CTLs could recognize endogenous antigen on allogeneic breast cancer cell line SK.BR.3. This is critically important because previously, many expanding techniques lead to CTLs that could only kill targets pulsed with related peptides but not targets that endogenously processed the antigen of interest [ 9]. Yee et al. [ 10, 11] found low affinity of induced CTLs leads to failure of recognition of endogenous antigen.

Thus, T2 cells have shown promise as a convenient tool to rapidly expand out Her-2/neu-specific CTLs in vitro. But so far, we are not able to transfer the expanded Her-2/neu-specific CTLs to breast cancer patients directly as they are mixed with T2 cells, and for the same reason, we cannot compare its anti-tumor effect with trastuzumab in breast cancer patients either. This technique might accelerate to study expanding CTLs in vitro and promote the development of safe and effective adoptive cancer immunotherapy in the future.